Intraventricular plus Intravenous Tigecycline for the Treatment of Daptomycin Nonsusceptible Vancomycin-Resistant Enterococci in an Infant with Ventriculoperitoneal Shunt Infection
2019
ABSTRACT VP shunt infection, which is one of the most important complications of ventriculoperitoneal (VP) shunt is observed at a rate of 4-17%.
Staphylococcus epidermidisis the most common causative agent.
Vancomycin-resistant Enterococcus(VRE) is an increasingly common nosocomial pathogen that rarely causes central nervous system (CNS) infections globally. Current treatment options that have shown appreciable activity against various VRE infections include
daptomycin,
linezolid, inquinupristin/
dalfopristin, and
tigecycline.
Daptomycinhas a peculiar mode of action and a potent bactericidal activity, making it a useful addition to the clinician’s antibiotic collection. Global surveillance data indicate less than 1.0% rates of
daptomycinresistance in enterococci.
Tigecyclineis a life-saving option in the treatment of resistant nosocomial infections but it has not yet been approved for use and there is not enough data in terms of dose and side effects associated with its use in children. Here, we describe the first case of the successful intraventricular plus intravenous use of
tigecyclineto treat VP shunt infections caused by
daptomycinresistant VRE faecium.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
24
References
5
Citations
NaN
KQI